Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
40.40
-0.52 (-1.27%)
At close: May 14, 2025, 4:00 PM
40.40
0.00 (0.00%)
After-hours: May 14, 2025, 4:36 PM EDT
Merus Revenue
Merus had revenue of $26.49M in the quarter ending March 31, 2025, with 235.76% growth. This brings the company's revenue in the last twelve months to $54.73M, up 42.77% year-over-year. In the year 2024, Merus had annual revenue of $36.13M, down -17.78%.
Revenue (ttm)
$54.73M
Revenue Growth
+42.77%
P/S Ratio
49.42
Revenue / Employee
$170,505
Employees
321
Market Cap
2.80B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 36.13M | -7.81M | -17.78% |
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRUS News
- 6 days ago - Merus to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 7 days ago - Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update - GlobeNewsWire
- 21 days ago - Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting - GlobeNewsWire
- 5 weeks ago - Merus: Riding The Bispecific Wave In Oncology - Seeking Alpha
- 6 weeks ago - Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewsWire
- 2 months ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma - GlobeNewsWire